









## Humber Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on May 2024

### Classification of products:

Status	Description
 <b>GREEN</b>	Medicines suitable for routine use within primary care and Secondary care. May be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies
 <b>AMB 1</b>	Specialist recommendation: These medicines are considered suitable for GP prescribing following specialist recommendation or via an APC approved prescribing guideline.
 <b>AMB 2</b>	Specialist initiation: These medicines are considered suitable for GP prescribing following specialist initiation, including titration of dose and assessment of efficacy. These medicines may also have an APC approved guideline to aid GPs in further prescribing.
 <b>AMB SCP</b>	AMBER SHARE CARE PROTOCOL- Specialist initiation with ongoing monitoring: Medicines that must be initiated by a specialist, and which require significant monitoring on an ongoing basis. Full agreement to share the care of each specific patient must be reached under the shared care protocol which must be provided to the GP. If a commissioned shared care is not available in CCG/place then these drugs must be treated as red drug (hospital only).
 <b>RED</b>	Red-Hospital initiation and continuation only
 <b>GREY</b>	GREY- NON FORMULARY (As agreed by Area Prescribing Committee)
 <b>PURPLE</b>	To be supplied from the appropriate commissioned provider.
 <b>NR</b>	Not routinely commissioned

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
<b>1) Requests deferred from previous meetings</b>				
Nil this month				
<b>2) New Requests</b>				
Arikayce® (liposomal amikacin)	<b>RED</b>			As per NHSE commissioning statement (HUTH)
Hylo-Dual Intense eye drops	<b>AMB 1</b>			On recommendation of ophthalmology only hyaluronic acid (0.2%) and ectoin 2%
Adex gel		X		
Target release budesonide	<b>RED</b>			TA937

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
Etrasimod	RED			TA956
Nicorette (quick mist)	PURPLE			
Duraphat toothpaste	PURPLE			AMB 1 on recommendation OMFS/restorative dentistry for patients without an NHS dentist.
<b>3) New formulations &amp; extensions to use</b>				
Nil this month				
<b>4) Products considered by NICE</b>				
<a href="#">TA953: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema</a>	RED			The formulary will reflect the TAG – ICS is the responsible commissioner.
<a href="#">TA954: Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments</a>	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<a href="#">TA956: Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over</a>	RED			The formulary will reflect the TAG – ICS is the responsible commissioner. Note: NHS England is the responsible commissioner for 16-17 years old.
<a href="#">TA957: Mometinib for treating myelofibrosis-related splenomegaly or symptoms</a>	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<a href="#">TA958: Ritlecitinib for treating severe alopecia areata in people 12 years and over</a>	RED			The formulary will reflect the TAG – ICS is the responsible commissioner for adult patients. NHS England is the responsible commissioner for 12-17 years age groups. Note: Referred to IPMOC due to financial impact / commissioning implications
<a href="#">TA959: Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis</a>	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
<a href="#"><u>TA962: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy</u></a>	<b>RED</b>			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<b>5) Appeals against earlier decisions by the APC</b>				
Nil this month				
<b>6) Miscellaneous formulary decisions by the APC</b>				
Nil this month				

The following guidelines were presented to and approved at the May 2024 meeting of the APC:

- Ocular Lubricant
- IBD guideline (HUTH only)

The following Drug information leaflets were presented to and approved at the May 2024 meeting of the APC:

- Nil this month

The following shared care guidelines were presented to and approved at the May 2024 meeting of the APC:

- Nil this month

Other documents presented to and approved at the May 2024 meeting of the APC:

- Nil this month